UK markets closed
NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.74 (-0.93%) GOLD FUTURES
2,428.40 -10.10 (-0.41%) DOW
39,862.73 +55.96 (+0.14%) Bitcoin GBP
54,556.46 -328.86 (-0.60%)
Ionis Pharmaceuticals Inc (ISI.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 07:08PM CEST. Market open.
| Previous close | 34.14 |
| Open | 35.40 |
| Bid | 34.36 x 50000 |
| Ask | 34.75 x 50000 |
| Day's range | 34.86 - 36.11 |
| 52-week range | 34.14 - 48.76 |
| Volume | |
| Avg. volume | 21 |
| Market cap | 4.21B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
- Reuters
REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study. Shares of Biogen and Ionis were each down nearly 2% in premarket trading. This marks another setback in the search for new treatments for ALS, a rare neurodegenerative disease that affects the voluntary control of limbs and leads to breathing trouble.
- Simply Wall St.
The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) shareholders are probably feeling a little disappointed, since its shares...
© 2024 Yahoo. All rights reserved.